Shenzhen JYMed Technology Co., Ltd. (nan gaba ake magana a kai a matsayin JYMed) an kafa a 2009, ƙware a cikin bincike, ci gaba, samarwa, da kuma tallace-tallace na peptides da peptide alaka kayayyakin. Tare da cibiyar bincike guda ɗaya da manyan sansanonin samarwa guda uku, JYMed yana ɗaya daga cikin manyan masu samar da peptide API ɗin da aka haɗa ta sinadarai a cikin Sin. Babban ƙungiyar R&D na kamfanin yana alfahari sama da shekaru 20 na gogewa a cikin masana'antar peptide kuma ta sami nasarar wuce binciken FDA sau biyu. JYMed ta m da ingantaccen tsarin masana'antu peptide masana'antu yayi abokan ciniki cikakken kewayon ayyuka, ciki har da ci gaba da kuma samar da warkewa peptides, dabbobi peptides, antimicrobial peptides, da kwaskwarima peptides, kazalika da rajista da kuma kayyade goyon baya.

Babban Ayyukan Kasuwanci

1.Domestic da na duniya rajista na peptide APIs

2.Veterinary da na kwaskwarima peptides

3.Custom peptides da CRO, CMO, OEM ayyuka

4.PDC kwayoyi (peptide-radionuclide, peptide-kananan kwayoyin halitta, peptide-protein, peptide-RNA)

Baya ga Tirzepatide, JYMed ya ƙaddamar da takaddun rajista tare da FDA da CDE don wasu samfuran API da yawa, gami da shahararrun magungunan ajin GLP-1RA a halin yanzu kamar Semaglutide da Liraglutide. Abokan ciniki na gaba masu amfani da samfuran JYMed za su iya yin la'akari kai tsaye lambar rajistar CDE ko lambar fayil ɗin DMF lokacin ƙaddamar da aikace-aikacen rajista ga FDA ko CDE. Wannan zai rage mahimmancin lokacin da ake buƙata don shirya takaddun aikace-aikacen, da kuma lokacin kimantawa da farashin bitar samfur.